Development and validation of a robust multigene signature as an aid to predict early relapse in stage I-III clear cell and papillary renal cell cancer

Conclusion: The 17 mRNAs signature could classify stage I-III RCC patients into low- or high-risk of early-relapse, and will help to guide interventions to optimize survival outcomes.

Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Da-Long Cao, Wei-Xing Dai, Yong-Qiang Huang, Lei-Jun Yu, Jun-Long Wu, Guo-Hai Shi, Hai-Liang Zhang, Yao Zhu, Bo Dai, Ding-Wei Ye Tags: Research Paper Source Type: research